Abstract:Regulated cell death (RCD) is a controlled form of cell death orchestrated by one or more cascading signaling pathways, making it amenable to pharmacological intervention. RCD subroutines can be categorized as apoptotic or non-apoptotic and play essential roles in maintaining homeostasis, facilitating development, and modulating immunity. Accumulating evidence has recently revealed that RCD evasion is frequently the primary cause of tumor survival. Several non-apoptotic RCD subroutines have garnered attention as promising cancer therapies due to their ability to induce tumor regression and prevent relapse, comparable to apoptosis. Moreover, they offer potential solutions for overcoming the acquired resistance of tumors toward apoptotic drugs. With an increasing understanding of the underlying mechanisms governing these non-apoptotic RCD subroutines, a growing number of small-molecule compounds targeting single or multiple pathways have been discovered, providing novel strategies for current cancer therapy. In this review, we comprehensively summarized the current regulatory mechanisms of the emerging non-apoptotic RCD subroutines, mainly including autophagy-dependent cell death, ferroptosis, cuproptosis, disulfidptosis, necroptosis, pyroptosis, alkaliptosis, oxeiptosis, parthanatos, mitochondrial permeability transition (MPT)-driven necrosis, entotic cell death, NETotic cell death, lysosome-dependent cell death, and immunogenic cell death (ICD). Furthermore, we focused on discussing the pharmacological regulatory mechanisms of related small-molecule compounds. In brief, these insightful findings may provide valuable guidance for investigating individual or collaborative targeting approaches towards different RCD subroutines, ultimately driving the discovery of novel small-molecule compounds that target RCD and significantly enhance future cancer therapeutics.

Small-molecule Compounds Target Paraptosis to Improve Cancer Therapy

Exploring paraptosis as a therapeutic approach in cancer treatment

Targeting paraptosis in cancer: opportunities and challenges

Paraptosis: a non-classical paradigm of cell death for cancer therapy

Parthanatos And Its Associated Components: Promising Therapeutic Targets For Cancer

Targeting Programmed Cell Death Using Small-Molecule Compounds To Improve Potential Cancer Therapy

Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy

Targeting Regulated Cell Death with Pharmacological Small Molecules: an Update on Autophagy-Dependent Cell Death, Ferroptosis, and Necroptosis in Cancer

Small molecules targeting tumor apoptosis related proteins and genes

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Non-apoptotic cell death in malignant tumor cells and natural compounds

Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance

Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine

Paraptosis—A Distinct Pathway to Cell Death

Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy

Progress in phytochemicals′ induction of autophagic cell death in cancer cells and regulation of nuclear receptors

Caspase-Mediated Programmed Cell Death Pathways As Potential Therapeutic Targets in Cancer

Targeting Cellular Proapoptotic Molecules for Developing Anticancer Agents from Marine Sources

Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives

Targeting Necroptosis in Anticancer Therapy: Mechanisms and Modulators

Targeting Cellular Apoptotic Pathway with Peptides from Marine Organisms